08045804946
Send Inquiry
FULZOS 250MG INJ
2800.0 INR/Box
Product Details:
- Life Span 24 months from manufacturing date
- Indication Hormone receptor-positive metastatic breast cancer in postmenopausal women
- Pacakaging (Quantity Per Box) 1 vial per box
- Packaging Type Vial with outer carton
- Salt Composition Fulvestrant 250mg
- Brand Name FULZOS 250MG INJ
- Dosage Form Parenteral injection
- Click to View more
X
FULZOS 250MG INJ Price And Quantity
- 1 Number
- 2800.0 INR/Box
- Celon Laboratories Ltd.
- Clear, colorless to yellowish, viscous liquid
- Intramuscular (IM)
- 2 years from date of manufacture
- As directed by oncologist
- Yes
- Injection site pain, hot flashes, nausea, fatigue
- Anticancer
- Hypersensitivity to fulvestrant or any excipients
- For hospital use only, not for self-administration
FULZOS 250MG INJ Product Specifications
- 250 mg administered intramuscularly
- FULZOS 250MG INJ
- Allopathic
- Parenteral injection
- Fulvestrant 250mg per vial
- India
- Administer under the supervision of a registered medical practitioner
- Store below 25C. Protect from light. Do not freeze.
- Vial with outer carton
- Injection
- Antineoplastic (breast cancer treatment)
- Fulvestrant 250mg
- Adults, mainly postmenopausal women with hormone receptor-positive metastatic breast cancer
- 1 vial
- Adults
- 1 vial per box
- Hormone receptor-positive metastatic breast cancer in postmenopausal women
- 24 months from manufacturing date
- Celon Laboratories Ltd.
- Clear, colorless to yellowish, viscous liquid
- Intramuscular (IM)
- 2 years from date of manufacture
- As directed by oncologist
- Yes
- Injection site pain, hot flashes, nausea, fatigue
- Anticancer
- Hypersensitivity to fulvestrant or any excipients
- For hospital use only, not for self-administration
FULZOS 250MG INJ Trade Information
- 1000 Number Per Week
- 2 Days
- No
- Asia, Middle East, Africa, Australia, Central America, North America, South America, Eastern Europe, Western Europe
- All India
Product Description
- Active Ingredient: Fulvestrant 250 mg/5 ml solution for injection.
- Class: Estrogen receptor antagonist (an estrogen blocker) and antineoplastic drug.
- How it Works: Many breast cancers have estrogen receptors and depend on the hormone estrogen to grow. Fulvestrant works by binding to these estrogen receptors and blocking the action of estrogen on the cancer cells. This causes the receptors to degrade, slowing down or stopping the growth of the tumor cells.
Uses
Fulzos 250 mg is used in postmenopausal women with:
- Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
- Cancer that has progressed after prior treatment with other anti-estrogen medications.
- It may be used alone (monotherapy) or in combination with other anti-cancer medications like palbociclib or abemaciclib
Specialized Cancer Care for Women
FULZOS 250MG INJ is specifically formulated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. By targeting hormone receptors, it helps slow cancer progression and can improve outcomes in eligible patients. It is part of a comprehensive treatment plan developed by oncologists to address advanced breast cancer.
Safe Administration and Handling
FULZOS 250MG INJ must only be given by registered medical professionals in a hospital setting. The injection is administered intramuscularly, ensuring the medicine is delivered efficiently into the body. Strict adherence to storage and administration guidelines guarantees the product's effectiveness and patient safety.
Quality Assurance and Storage
Each vial of FULZOS comes securely packaged, with a shelf life of 24 months from the date of manufacture when stored below 25C and protected from light. The clear to yellowish solution is easy to visually inspect for quality before use, and healthcare professionals ensure the correct dosage and handling every time.
FAQ's of FULZOS 250MG INJ:
Q: How should FULZOS 250MG INJ be administered?
A: The injection is administered as a 250 mg intramuscular dose by a registered medical practitioner, typically into the buttock muscle, in a hospital or oncology clinic. Self-administration is not recommended.Q: What is the main therapeutic use of FULZOS 250MG INJ?
A: FULZOS 250MG INJ is used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women as directed by an oncologist.Q: When is the best time to receive this medication?
A: The timing and frequency are determined by the oncologist's protocol. It is usually given at regular intervals as part of a scheduled cancer treatment plan.Q: Where should FULZOS 250MG INJ be stored before use?
A: Store the injection below 25C, protected from light, and never freeze it. Pharmacy staff ensure proper storage before administration.Q: What are the possible side effects of this medicine?
A: Common side effects include injection site pain, hot flashes, nausea, and fatigue. Inform your healthcare provider if you experience any unusual symptoms.Q: Who should not receive FULZOS 250MG INJ?
A: People with known hypersensitivity to fulvestrant or any excipients in FULZOS should not receive this injection. Always consult your oncologist about your medical history.Q: What are the benefits of using FULZOS 250MG INJ?
A: The main benefit is its targeted action against hormone receptor-positive metastatic breast cancer, helping to slow down or stop the growth of cancer cells in postmenopausal women.Tell us about your requirement
Price:
Quantity
Select Unit
- 50
- 100
- 200
- 250
- 500
- 1000+
Additional detail
Mobile number
Email
Other Products in 'Anti Cancer Medicines' category
Contact Us
- Office No. - 5, Ground Floor, D R Shopping Center, Dattapada Road, Near Hdfc Bank, Borivali East,Mumbai - 400066, Maharashtra, India
- Phone : 08045804946
- Mr Ranjeet Singh (CEO & Founder)
- Mobile : 08045804946
- medisus.pharma007@gmail.com
Send Inquiry
Send SMS
Call Me FreeMEDISUS PHARMA
All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.
Developed and Managed by Infocom Network Private Limited.
